ZENITH HEALTH CARE LTD. is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 22 | 13 | 14 | 11 | 11 |
| EBITDA (ex other income) | 0 | 0 | 0 | 0 | (0) |
| margin % | 2.0 | 0.2 | 1.6 | 0.8 | (1.2) |
| Owners' profit | 0 | 0 | 0 | 0 | 0 |
| EPS, as reported (₹) | 0.06 | 0.01 | 0.04 | 0.01 | 0.01 |
| ROE % · ROCE % | 4.3 · 8.7 | 1.1 · 1.7 | 2.8 · 3.9 | 0.9 · 3.9 | 0.1 · 0.3 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 1 | (1) | 2 | 1 | (1) |
| Capex | 0 | 0 | (0) | (0) | (0) |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 3 | 2 | 3 | 3 | 2 | 2 | 3 |
| Profit before tax | 0 | 0 | (0) | 0 | (0) | 0 | 0 | (0) |
| Net profit | 0 | 0 | (0) | 0 | (0) | 0 | 0 | (0) |
| EPS (₹) | 0.03 | 0.02 | (0.05) | 0.02 | 0.01 | 0.03 | 0.04 | 0.06 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 31 Aug 2026 · Re-appointment of Non-Executive Director Mrs. Neela M. Raycha via rotation | management changes | low | — | — |
| 31 Aug 2026 · Zenith Healthcare shareholders approve Joint MD Akshit Raycha for 3 years | management changes | medium | — | — |
| 31 Aug 2026 · Re-appointment of Mr. Mahendra C. Raycha as Managing Director for 3 more years | management changes | medium | — | — |
| 31 Aug 2026 · All 5 resolutions passed at 32nd AGM; MD reappointed for 3 more years | compliance | minimal | — | — |
| 28 Aug 2026 · 32nd AGM held on Aug 28, 2026 via VC, 5 resolutions passed | board shareholder meetings | low | — | — |
| 28 Aug 2026 · Zenith Healthcare 32nd AGM held on Aug 28, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 19 Aug 2026 · Zenith Healthcare files Q1FY26 results in newspapers | compliance | minimal | — | — |
| 14 Aug 2026 · Q1 FY27 Results: Revenue up, swings to Rs 13.62 lakh profit | results | medium | — | — |
| 14 Aug 2026 · Q1 FY27 Results Approved: Revenue Rs 343L, PAT Rs 14L vs Loss Last Year | results | high | — | — |
| 7 Aug 2026 · Board Meeting on Aug 14, 2026 to Consider Q1 FY27 Results | results | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 22.4 | 28.9 | 63 of 169 | 63% |
| P/B | 2.3 | 3.3 | 58 of 163 | 65% |
| ROCE | 0.2 | 10.8 | 151 of 183 | 18% |
| ROE | 0.1 | 10.4 | 146 of 171 | 15% |
| Debt / Equity | 0.0 | 0.1 | 6 of 171 | 77% |
| EBITDA margin | (13.7) | 17.5 | 161 of 165 | 2% |
| Revenue growth | (23.5) | 16.3 | 143 of 161 | 11% |
| Profit growth | (411.5) | 30.9 | 156 of 158 | 1% |
| Market cap | 17 | 839 | 168 of 182 | 8% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
